Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NVO

Novo Nordisk ADR

Mar 10 • 04:00PM ET

38.72

-1.06 -2.66 %

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Today, 5:56 AMTD Cowen downgrades Novo Nordisk ADR to Hold from Buy and cuts price target to $42 from $45

Peers: LLY MRK ABBV JNJ AMGN AZN-D PFE SNY BMY GSK

| Held by: PVAL PPH AVDE FTHI PINK WCMI PID AQEC OZEM APIE

Scroll to Statements

Index	-	P/E	11.16	EPS (ttm)	3.47	Insider Own	0.01%	Shs Outstand	3.37B	Perf Week	5.62%
Market Cap	130.45B	Forward P/E	11.29	EPS next Y	3.43	Insider Trans	0.00%	Shs Float	3.37B	Perf Month	-18.72%
Enterprise Value	146.81B	PEG	10.75	EPS next Q	0.92	Inst Own	9.44%	Short Float	0.80%	Perf Quarter	-19.10%
Income	15.45B	P/S	2.79	EPS this Y	-7.80%	Inst Trans	-0.40%	Short Ratio	1.11	Perf Half Y	-28.67%
Sales	46.77B	P/B	5.64	EPS next Y	2.25%	ROA	20.59%	Short Interest	26.97M	Perf YTD	-23.90%
Book/sh	6.87	P/C	30.77	EPS next 5Y	1.05%	ROE	61.25%	52W High	82.57 -53.11%	Perf Year	-50.96%
Cash/sh	1.26	P/FCF	14.58	EPS past 3/5Y	26.28% 20.36%	ROIC	31.38%	52W Low	35.85 8.01%	Perf 3Y	-45.19%
Dividend Est.	1.67 (4.32%)	EV/EBITDA	6.49	Sales past 3/5Y	23.19% 19.21%	Gross Margin	80.90%	Volatility	2.87% 2.52%	Perf 5Y	7.96%
Dividend TTM	1.73 (4.46%)	EV/Sales	3.14	EPS Y/Y TTM	5.57%	Oper. Margin	41.17%	ATR (14)	1.84	Perf 10Y	38.46%
Dividend Ex-Date	Mar 30, 2026	Quick Ratio	0.57	Sales Y/Y TTM	11.11%	Profit Margin	33.03%	RSI (14)	34.19	Recom	2.53
Dividend Gr. 3/5Y	28.28% 20.66%	Current Ratio	0.80	EPS Q/Q	3.95%	SMA20	-9.04%	Beta	0.74	Target Price	50.66
Payout	38.07%	Debt/Eq	0.67	Sales Q/Q	0.66%	SMA50	-23.75%	Rel Volume	0.83	Prev Close	39.78
Employees	68794	LT Debt/Eq	0.61	Earnings	Feb 04 BMO	SMA200	-31.08%	Avg Volume	24.20M	Price	38.72
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.40% 3.10%	Trades		Volume	20,037,588	Change	-2.66%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral
Jul-31-25	Downgrade	HSBC Securities	Buy → Hold	$57
Jul-30-25	Downgrade	Barclays	Overweight → Equal Weight
Apr-17-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$64

Show Previous Ratings

Today 04:04PM	Novo Nordisk Warned by FDA Over Adverse Event Reporting (GuruFocus.com)
03:02PM	What's Driving Attention Behind These Trending Stocks? MRVL, STRL, HIMS (Zacks)
02:42PM	Hims & Hers Stock Upgraded After Novo Nordisk Agreement. Why It Isn't a Buy Yet. (Barrons.com)
02:39PM	Eli Lilly Says Some Medicare GLP-1 Patients May Pay Above $50 Under New CMS Model (GuruFocus.com)
02:38PM	Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs (Insider Monkey)
02:03PM	Loading…
02:03PM	Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal (MarketBeat)
01:01PM	What's Fueling The Rise In Hims & Hers Health Stock Today? (Benzinga)
12:45PM	GLP-1 weight-loss drug race heats up as new rival matches Wegovy results with fewer side effects (Proactive)
12:05PM	Wall Street Gets Less Bearish on Hims & Hers After Novo Nordisk Truce. Stock Gains Could Still Be Limited. (Barrons.com)
10:23AM	Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit (24/7 Wall St.)
09:34AM	Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls (The Fly)
08:21AM	Novo Nordisk downgraded as pipeline not poised to blunt semaglutide LOE (Investing.com)
08:06AM	Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe's,Qualcomm, Rivian, Strategy and More (24/7 Wall St.)
07:40AM	Novo and Hims & Hers become partners to end legal feud (Pharmaceutical Technology)
05:48AM	Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen. (MarketWatch)
04:18PM	Loading…
Mar-09-26 04:18PM	Uber expands Women Preferences, Hims & Hers stock skyrockets (Yahoo Finance Video)
04:02PM	Novo Nordisk deal lets Hims sell Wegovy and Ozempic, drops lawsuit (USA TODAY)
03:32PM	Hims & Novo Call a Truce, Hims Gets Exactly What It Wanted (Moby)
03:30PM	Hims & Hers rockets higher on potential Novo Nordisk deal (GuruFocus.com)
03:23PM	Stock Of The Day: Will Hims & Hers Go Into Another Short Squeeze? (Benzinga)
02:54PM	Hims & Hers Jumps 47% as Novo Nordisk Weighs New Weight-Loss Drug Partnership (GuruFocus.com)
02:34PM	Nasdaq stays green as Middle East war sends oil above $103 (Proactive)
02:27PM	Hims and Novo End Feud With Obesity Drug Deal (GuruFocus.com)
01:18PM	Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic (Reuters Videos)
01:17PM	Hims & Hers Shares Surge on Novo Nordisk Deal Report (GuruFocus.com)
01:11PM	Hims & Hers stock skyrockets 40% as Novo Nordisk ends feud, agrees to sell Ozempic and Wegovy on platform (MarketWatch)
12:51PM	Hims & Hers Stock Jumps on Reports Novo Nordisk Obesity Deal (GuruFocus.com)
12:15PM	Hims & Hers Stock Soars. Its Weight-Loss Drug Battle With Novo Nordisk Takes a Surprising Twist. (Barrons.com)
11:16AM	Pre-Markets in the Red as Geopolitical Tensions Escalate (Zacks)
11:13AM	Hims partners with Novo Nordisk, Live Nation settles antitrust suit (Yahoo Finance Video)
11:08AM	Loading…
11:08AM	Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform (Yahoo Finance)
11:04AM	Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute (Proactive)
10:35AM	HIMS Stock Eyes Best Day Ever After Dispute Dissolution (Schaeffer's Research)
10:18AM	Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration (Associated Press Finance)
10:17AM	Pre-Markets Down as Middle East Tensions Remain (Zacks)
10:01AM	Hims & Hers agrees to stop selling compound versions of Novo Nordisk's Wegovy and other weight-loss drugs, ending suit (Associated Press Finance)
09:53AM	Hims & Hers Catapults After Settling Its Bloody Saga With Novo Nordisk (Investor's Business Daily)
09:52AM	Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers (The Wall Street Journal)
09:38AM	Hims & Hers Stock Pops on a Deal With Rival Novo NordiskWhat You Need to Know (Investopedia)
09:35AM	Hims & Hers Stock Surges as Novo Nordisk Deal Ends Legal Dispute (The Wall Street Journal)
09:34AM	Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs (Investor's Business Daily)
09:05AM	NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell? (Zacks)
09:02AM	Hims & Hers will sell real Ozempic in deal with Novo Nordisk (Quartz)
08:09AM	Roche's Breast Cancer Drug Falls Short In Phase 3 Study (Benzinga)
07:04AM	Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars (Benzinga)
07:00AM	Hims And Hers Surges Over 50% On Deal To Sell Novo Nordisk Obesity Drugs (Investor's Business Daily)
06:25AM	These Stocks Are Todays Movers: Chevron, Hims & Hers, Carnival, Delta, Newmont, Vertiv, and More (Barrons.com)
06:06AM	Hims & Hers Shares Double on Report of Wegovy Tie-Up (The Wall Street Journal)
05:43AM	Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer, Hims & Hers (The Wall Street Journal)
05:34AM	Hims soars 44% on report Novo Nordisk to sell weight-loss drugs on its platform (Investing.com)
05:28AM	Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike-Hims & Hers, Ovintiv, Uniqure In Focus (Benzinga)
04:32AM	Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From Underweight - Here's Why (Insider Monkey)
Mar-07-26 10:56AM	Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce (24/7 Wall St.)
Mar-06-26 09:52PM	Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report (Benzinga)
02:46PM	Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B (Insider Monkey)
01:09PM	Study Says Ozempic Knockoffs Could Cost $3 (GuruFocus.com)
11:28AM	Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal (Zacks)
09:00AM	Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:41AM	Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market (The Wall Street Journal)
08:14AM	China Clears Weight-Loss Shot As Pfizer Enters Crowded Market (Benzinga)
06:47AM	Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk And Eli Lilly (Benzinga)
04:20AM	Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial (The Wall Street Journal)
03:47AM	Novo (NVO) Announces Investment in Ireland To Boost Production (Insider Monkey)
Mar-05-26 10:10PM	Lexicon Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:35PM	Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
08:12AM	Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? (Zacks)
Mar-04-26 12:41PM	Looking For A Rebound? China Tech and Emerging Markets Top Oversold List (Benzinga) +5.02%
12:18PM	Hims & Hers Slips as FDA Targets GLP-1 Compounders (GuruFocus.com)
12:16PM	Novo Nordisk Gets FDA Warning Over Ozempic Ad (GuruFocus.com)
08:01AM	EXCLUSIVE: Hoth Therapeutics Integrates OpenAI API To Support Drug Development For Aggressive Cancers (Benzinga)
Mar-03-26 09:33AM	MongoDB downgraded, Block upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More (24/7 Wall St.)
07:08AM	Novo Nordisk starts 432m Ireland facility upgrade for oral Wegovy production (Pharmaceutical Technology)
05:06AM	Morgan Stanley upgrades Novo Nordisk, says risks better priced after sell-off (Investing.com)
Mar-02-26 02:45PM	Novo Nordisk to Invest $506 Million in Ireland for Wegovy Production (GuruFocus.com)
11:00AM	Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026? (Zacks)
09:16AM	Analysis-Hims expansion may not come in time for risky GLP-1 business (Reuters)
08:50AM	Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins? (Zacks)
07:56AM	Here Are Mondays Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More (24/7 Wall St.)
Mar-01-26 12:31PM	Novo Nordisk, First Solar, And Corebridge Financial Are Among Top 10 Large Cap Losers Last Week (Feb. 23-Feb. 27): Are the Others in Your Portfolio? (Benzinga)
04:27AM	Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya (Insider Monkey)
Feb-28-26 06:00AM	Denmarks fat jab champion is slimming down the whole economy (The Telegraph)
02:21AM	Novo Nordisk A/S (NVO) and Vivtex Corporation Announce a Partnership (Insider Monkey)
Feb-27-26 01:35PM	Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival (GuruFocus.com)
01:30PM	Watch: Why Eli Lilly Is Winning the Weight-Loss War (The Wall Street Journal)
11:04AM	Stock Market Can't Hold Key Levels Amid AI Concerns; Nvidia Tumbles Despite Strong Earnings: Weekly Review (Investor's Business Daily)
05:56AM	Novo Nordisks Torrid Week Erases Last of Wegovy-Fueled Gains (Bloomberg)
Feb-26-26 12:59PM	Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 (Benzinga)
09:56AM	Jim Cramer Recommends Eli Lilly over Novo Nordisk (Insider Monkey)
08:30AM	Novavax, Inc. Q4 2025 Earnings Call Summary (Moby)
07:39AM	For the first time in decades, new hair-loss treatments are in the works. Heres how theyre different. (MarketWatch)
07:10AM	Lillys GLP-1 pill tops Novos Rybelsus in head-to-head trial (BioPharma Dive)
06:42AM	Anthropic Excites But Doesn't Replace (GuruFocus.com)
05:44AM	Novo Nordisk and Vivtex collaborate for oral medicines development (Pharmaceutical Business Review)
Feb-25-26 11:31PM	Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight (Benzinga)
03:36PM	For the first time in decades, new hair-loss treatments are in the works. Here's how they're different. (MarketWatch)
01:42PM	Ozempic, Wegovy list prices to be slashed by up to 50% (NY Daily News)
01:01PM	Novo Partners Vivtex in Deal Worth Up to $2.1 Billion (GuruFocus.com)
12:47PM	Novo Nordisk Strikes Up to $2.1B Vivtex Deal for Oral Obesity Drugs (GuruFocus.com)
11:33AM	Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment (Benzinga)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience